Lecanemab for Early Onset Familial Alzheimer's Disease

Recruiting now

Conditions studied: Alzheimer Disease

In brief

The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.

Key facts

Study ID: NCT06883019
Run by: RenJi Hospital
People needed: 114
Starts: 2025-03-13
Expected to finish: 2027-08-31
Last updated by the study team: 2025-03-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age at onset ≤ 65 years, with a minimum age of 18 years; no restriction on gender.
Diagnosis of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): Must meet the clinical diagnostic criteria for AD-related MCI and mild AD as defined by the National Institute on Aging and the Alzheimer's Association (NIA-AA) (2011); confirmed Aβ positivity through Aβ-PET/CT, Aβ-PET/MRI, or cerebrospinal fluid testing.
MMSE ≥ 21 or MoCA ≥ 17 or CDR = 0.5
No significant signs found in the neurological examination
Participants must be capable of completing cognitive assessments and other tests.
Informed consent must be obtained from the participants and their legal guardians, with a dated signature, prior to any operations or tests related to the protocol, committing to comply with the research procedures and cooperate throughout the study process.

You may not qualify if…

Cognitive decline caused by other reasons: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (drugs, alcohol, CO, etc.), significant systemic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural hematoma, brain tumor), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiencies or any other reasons.
Patients with other unstable diseases, or those who have had a stroke or transient ischemic attack, bleeding disorders, or seizures within the previous 12 months.
Patients with psychiatric disorders who meet DSM-IV criteria for schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium.
Patients with unstable or severe heart, lung, liver, kidney, hematological diseases; those with known malignancies or other serious prognoses.
Exclusion of cerebral amyloid angiopathy-related inflammation/β-amyloid-related cerebral vasculitis (CAAri/ABRA).
Presence of uncorrectable visual or auditory impairments that prevent completion of relevant assessments or scales.
Patients who cannot undergo MRI due to claustrophobia, pacemakers, defibrillators, or metal implants.
MRI findings showing more than four microhemorrhages (diameter < 10 mm), evidence of surface iron deposition, vascular edema, diffuse white matter disease, multiple lacunar strokes, or any strokes involving major vascular regions. Presence of evidence of cerebral contusions, brain softening, cerebral aneurysms, or other vascular malformations, central nervous system (CNS) infections, as well as brain tumors other than meningiomas or arachnoid cysts.
Patients taking warfarin, vitamin K antagonists, or direct oral anticoagulants (dabigatran, rivaroxaban, edoxaban, apixaban, betrixaban) or heparin; patients receiving thrombolysis; patients with coagulation disorders.
Pregnant or lactating women.
Patients deemed unsuitable for use by clinicians apart from the exclusion criteria listed above.
Patients with severe allergies to lecanemab or any excipients of this product.

Where it is running

Xuanwu Hospital, Capital Medical University — Beijing, China, China (enrolling)
The Second Affiliated Hospital of Guangzhou Medical University — Guangdong, China, China (enrolling)
The Affiliated Hospital of Guizhou Medical University — Guizhou, China, China (enrolling)
Nanjing Brain Hospital — Jiangsu, China, China (enrolling)
Nanjing Drum Tower Hospital — Jiangsu, China, China (enrolling)
Nantong First People's Hospital — Jiangsu, China, China (enrolling)
Huadong Hospital, Fudan University — Shanghai, China, China (enrolling)
Renji Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China, China (enrolling)
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China, China (enrolling)
Shanghai Mental Health Center — Shanghai, China, China (enrolling)
West China Hospital of Sichuan University — Sichuan, China, China (enrolling)
Tianjin Medical University General Hospital — Tianjin, China, China (enrolling)
Jinhua Central Hospital — Zhejiang, China, China (enrolling)
Ningbo Second Hospital — Zhejiang, China, China (enrolling)
The First Affiliated Hospital, Zhejiang University School of Medicine — Zhejiang, China, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.